Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
At the Neuroendocrine Tumor Research Foundation (NETRF), we believe that the path to better treatments and cures, starts with research. However, ensuring that we fund
By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded
At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is
By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread
By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs) A study published this month by NETRF-funded Collaborative Grant
Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the